Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”

Detalles Bibliográficos
Autores principales: Kant, Agnes, van Hunsel, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284101/
https://www.ncbi.nlm.nih.gov/pubmed/35838877
http://dx.doi.org/10.1007/s40264-022-01207-x
_version_ 1784747482983432192
author Kant, Agnes
van Hunsel, Florence
author_facet Kant, Agnes
van Hunsel, Florence
author_sort Kant, Agnes
collection PubMed
description
format Online
Article
Text
id pubmed-9284101
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92841012022-07-15 Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands” Kant, Agnes van Hunsel, Florence Drug Saf Letter to the Editor Springer International Publishing 2022-07-15 2022 /pmc/articles/PMC9284101/ /pubmed/35838877 http://dx.doi.org/10.1007/s40264-022-01207-x Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Letter to the Editor
Kant, Agnes
van Hunsel, Florence
Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”
title Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”
title_full Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”
title_fullStr Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”
title_full_unstemmed Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”
title_short Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”
title_sort authors’ reply to mungmunpuntipantip et al.’s comment on “description of frequencies of reported adverse events following immunization among four different covid-19 vaccine brands”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284101/
https://www.ncbi.nlm.nih.gov/pubmed/35838877
http://dx.doi.org/10.1007/s40264-022-01207-x
work_keys_str_mv AT kantagnes authorsreplytomungmunpuntipantipetalscommentondescriptionoffrequenciesofreportedadverseeventsfollowingimmunizationamongfourdifferentcovid19vaccinebrands
AT vanhunselflorence authorsreplytomungmunpuntipantipetalscommentondescriptionoffrequenciesofreportedadverseeventsfollowingimmunizationamongfourdifferentcovid19vaccinebrands

Ejemplares similares